Trial Time , MND , SARs / Covid

Great to hear that the newly formulated MPL tablets for Human Trials have been manufactured.

The MND Trial Patient recruitment will now begin for a truly debilitating disease..

Then the long awaited SARs/Covid Trial can begin ,, with so much compelling data surrounding SARs/ Covid vs MPL I feel this will act as real catalyst driving tremendous interest toward Pharmaust.

Preliminary Positive Results for the Treatment of SARS-CoV-2 Viral Infection by Monepantel
https://stocknessmonster.com/announcements/paa.asx-6A981296/

Confirmation of Preliminary COVID-19 Results Following
Monepantel Treatment In Vitro
https://stocknessmonster.com/announcements/paa.asx-6A982977/

Inhibition of SARS-CoV-2 by Monepantel in Preliminary
Studies of Human Respiratory Calu-3 Cells In Vitro
https://stocknessmonster.com/announcements/paa.asx-6A992675/

Monepantel Anti-viral Activity Against SARS-CoV-2
Confirmed
https://stocknessmonster.com/announcements/paa.asx-6A995129/

PharmAust and Leiden University Evaluate Monepantel
Suitability for Ex-Vivo Human COVID-19 Testing
https://stocknessmonster.com/announcements/paa.asx-6A997384/
Monepantel and monepantel sulfone COVID-19 anti-viral update
• Three individual laboratories have now examined the effects of monepantel (MPS) and
monepantel sulfone (MPLS) upon SARS-COV2 infection, the causal agent of COVID19 disease

• MPL and MPLS significantly protect against COVID-19 virus mediated cell death

• MPL and MPLS appear to inhibit viral infection by targeting late-stage events in the
COVID-19 virus life-cycle

• Evaluation of MPL in COVID-19 patients is being assessed in Europe for when GMP
grade tablets are manufactured

• PharmAust will continue to build its anti-viral preclinical data package by additionally
investigating MPL in HTLV-1 viral infections
26 July 2021 – Perth, Australia: PharmAust Limited (ASXAA), a clinical-stage biotechnology company, is
pleased to provide an update on its anti-viral program investigating the development of monepantel (MPL) and its
metabolite monepantel sulfone (MPLS) as anti-viral therapeutics against SARS-CoV2, the causal agent of
COVID-19 disease.
In collaboration with three independent laboratories, PharmAust has investigated the capacity of MPL and MPLS
in vitro to inhibit:
i) SARS-CoV2-induced cell death,
ii) SARS-CoV2 RNA release from the cell, and
iii) SARS-CoV2 RNA infection of neighbouring cells.
All three laboratories demonstrated that both MPL and MPLS protect against cell death in vitro following infection
with SARS-CoV2. Furthermore, two laboratories investigated the effects of MPL and MPLS upon the early stages
of the SARS-CoV2 virus lifecycle by examining RNA release into the culture media.

With such an amount of compelling Positive data from 3 Independent 3rd Party Research Institutes , as they say the proof is in the Pudding and Covid is about to get a dose of MPL...... Exciting Times ahead..